H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $68Market news · 18 Aug 2026
Stifel Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $40Market news · 17 Aug 2026
Guggenheim Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $35Market news · 12 Aug 2026
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Maze Therapeutics, Inc. (MAZE) and Xtant Medical Holdings (XTNT)TipRanks · 12 Aug 2026
Wedbush Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $39Market news · 12 Aug 2026
J.P. Morgan Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $46Market news · 15 Jul 2026
A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $35 to $42Market news · 9 Jun 2026
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Raises Target Price to $46Market news · 29 Jun 2026
Jefferies Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $60Market news · 26 Jun 2026
Jefferies Upgrades Tango Therapeutics(TNGX.US) to Buy Rating, Raises Target Price to $60Market news · 26 Jun 2026
CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $42Market news · 11 Jun 2026
H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $66Market news · 11 Jun 2026
A Quick Look at Today's Ratings for Tango Therapeutics(TNGX.US), With a Forecast Between $32 to $66Market news · 10 Jun 2026
Discussion
No comments yet — be the first to weigh in on TNGX.
No comments yet — be the first to weigh in on TNGX.